Pieris Pharmaceuticals (PIRS) Given a $12.00 Price Target at HC Wainwright
HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note issued to investors on Friday morning. The firm currently has a buy rating on the biotechnology company’s stock.
PIRS has been the topic of a number of other research reports. BidaskClub upgraded shares of Pieris Pharmaceuticals from a buy rating to a strong-buy rating in a research report on Monday, February 5th. ValuEngine lowered shares of Pieris Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, December 1st. Finally, William Blair started coverage on shares of Pieris Pharmaceuticals in a research report on Wednesday, January 17th. They set an outperform rating on the stock. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Pieris Pharmaceuticals has a consensus rating of Buy and a consensus target price of $10.00.
Pieris Pharmaceuticals (PIRS) opened at $8.59 on Friday. Pieris Pharmaceuticals has a 52-week low of $1.88 and a 52-week high of $8.79.
A number of institutional investors have recently modified their holdings of the business. Baird Financial Group Inc. acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $477,000. Arrowstreet Capital Limited Partnership acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $3,370,000. Virtus Fund Advisers LLC acquired a new stake in Pieris Pharmaceuticals in the fourth quarter valued at approximately $432,000. BlackRock Inc. boosted its position in Pieris Pharmaceuticals by 4.4% in the fourth quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock valued at $12,053,000 after buying an additional 67,895 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its position in Pieris Pharmaceuticals by 354.8% in the fourth quarter. Wells Fargo & Company MN now owns 82,603 shares of the biotechnology company’s stock valued at $623,000 after buying an additional 64,439 shares in the last quarter. Hedge funds and other institutional investors own 50.10% of the company’s stock.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.